Sentences with phrase «pharma companies as»

How to Get Past the ATS and in Front of a Live Person Applicant Tracking Software (ATS) Systems are used by a majority of large medical device and pharma companies as part of a talent acquisition strategy and to manage job openings.

Applicant Tracking Software (ATS) Systems are used by a majority of large medical device and pharma companies as part of a talent acquisition strategy and to manage job openings.

The recent introduction of generic Lipitor in Canada is one example of the challenges facing pharma companies as current blockbusters come off patent and face generic competition.

Among them were a few specialty pharma companies as well as some biotechs.

Not exact matches

In B.C. especially, companies such as QLT Inc., Angiotech Pharmaceuticals and Cardiome Pharma Corp. saw their valuations soar in the early 2000s, only to come crashing to earth by the end of the decade as a result of competitive pressures, regulatory snags, strategic blunders and deals gone awry.

While the early - stage company still mounted losses for the quarter, it received more revenue than expected as a result of its collaboration with pharma giant Pfizer.

Others, such as consumer watchdog Public Citizen and the preventive medicine advocacy group Trust for America's Health (TFAH), had very different takes, arguing Cures mostly benefits pharma companies at the expense of other important public health initiatives.

Martin Shkreli, unaffectionately known as the «pharma bro» — and infamous for his decision to hike the list price of Daraprim, a drug used by HIV / AIDS and cancer patients to combat infections, by more than 5,000 % in 2015 under his former company Turing Pharmaceuticals — was convicted on three criminal securities fraud and conspiracy charges by a Brooklyn jury on Friday.

«On Nasdaq, the main investors for biotech stocks are mainly U.S. funds, but, in Hong Kong, we can better tap Chinese and Asian investors as we are closer to them,» said Yang Dajun, chairman of Ascentage Pharma, a Chinese biotech company.

Unlike many upstart pharma companies that must turn to the financial markets for expansion dollars, Prollenium's sales volume provided the cash it needed to finance new research and development, as well as a major capital project.

This can set you up also for more long term reputation rehabilitation by forcing a focus on Turing as a research and development company — not a pharma hedge fund hybrid.»

Ten of these companies, our honorees, have matched or outperformed the median annual revenue or profit for their peers in pharma, biotech, or tech, as tracked by EY and Capital IQ.

That deal cemented Actavis's rebirth as a branded and specialty pharma company — or as CEO Brent Saunders said, a pioneer «in a new industry model: Growth Pharma.&pharma company — or as CEO Brent Saunders said, a pioneer «in a new industry model: Growth Pharma.&Pharma.»

Many of the recent Big Pharma deals and acquisition proposals have been motivated by the companies» desire to lower their tax rate by acquiring a foreign rival and moving their headquarters overseas in a process known as an inversion.

Giddying merry - go - round of pharma deals continues as Israeli company creates the world's biggest maker of generics.

Even mighty Novartis, the No. 2 pharma company in the world after Johnson & Johnson (JNJ), trimmed four divisions as it built up its cancer portfolio.

One day I came home from working at a big pharma company that had the same type of elevator as my condo building in Toronto.

But as these recent fiery debates within the drug industry underscore, pharma's price hike tactics, now under constant public scrutiny, may well lead to more far - reaching change — whether imposed by legislation or by biopharma companies upon themselves.

It's possible that Paulson and Vanguard decided to invest their gains into other pharma companies developing new drugs, but they are just as likely to put their money somewhere else.

Immuno - oncolocy has been the focus of Big Pharma and biotechs alike, with companies such as Merck (mrk), Bristol - Myers Squibb (bmy), Pfizer (pfe), Roche / Genentech, Juno (juno), Kite Pharma (kite), Novartis (nvs), and countless others pouring massive investments into the space (the Loncar ETF contains almost all of these companies).

While Tesaro is remaining publicly coy for now, a buyout has always been in the cards as big pharma companies continue to snap up biotechs that have already done drug development legwork for them.

The Staywell half of the deal is arguably not an acquisition, as both companies were already subsidiaries of pharma giant Merck.

ICCR encourages pharma companies to share patents for their life - saving HIV drug formulations through the Medicines Patent Pool as a way to make them more affordable and available where they are needed most.

In general, I like consumer staples, utilities, pharma companies like JNJ, PG, KO, PM, SO, GSK, GILD as they are more predictable over a decent period of time and carry less volatility.

Immunotherapy has been emerging from the backdrop of oncology research for years most notably from smaller companies such as Dendreon, Kite Pharma and Juno Therapeutics as leaders in the space.

Purdue Pharma executives saw Mr. Giuliani as that person, said a former company spokesman.

Another dream of a company would be Pure Pharma as well.

Mitzi has served as a nutrition spokesperson for numerous companies including: Fiji Water, The National Honey Board, Sambazon, Horizon Organic, Reynold's Wrap, USA Pears, Olive Oil Association, The Hass Avocado Board, Almond Board of California, Wild Blueberries, The Cherry Marketing Institute, Cranberry Marketing Committee, Back to Nature, Bayer Aspirin, Bausch and Lomb, Purdue Pharma, and Green Giant.

Constantia Flexibles (www.cflex.com), a world leading manufacturer of flexible packaging products and labels that supplies multinational corporations and local market leaders in the food, pet food, pharmaceuticals and beverage industries, has hired Dr. Ibon Odriozola as head of innovation, laminates for the company's pharma division.

Before joining Constantia Flexibles as Sales Director Pharma in July 2003, Bruchon worked for different packaging companies such as VAW Flexibles, AC Folien and Plastohm GmbH.

Tim Sykes spoke to Tiziano Petrucciani, quality & technical development director at Molteni Farmaceutici, the renowned Italian specialist in pharma R&D and production, about the company's collaboration with Rockwell Automation, using serialisation as a springboard for a profound modernisation of its manufacturing processes.

While Williams built his reputation on deals such as the merger of fertiliser giants Incitec and Pivot and more recently by advising Bega Cheese in the takeover battle of Warrnambool Cheese & Butter, he has dabbled in small pharma companies for years.

Companies namely, Kerry Group plc, Associated British Foods plc, Roquette Fréres S.A., DuPont, Ingredion Incorporated, Meggle AG, Hilmar Ingredients, JRS Pharma GmbH & Co.KG, Innophos, Inc., Cargill, Incorporated and IMCD Group B.V. are observed as the global leaders in nutraceutical excipients production.

«As a global company on the forefront of healthcare change, Astellas is proud to once again be a part of bringing international rugby back to Chicago, a great sporting city and the headquarters for Astellas in the Americas,» said James Robinson, president, Astellas Pharma US.

The space isn't only confined to pharma either, as science company DuPont also formed alliances with Lithuania's Vilnius University and Caribou Biosciences, with a specific interest in plant breeding and agricultural applications.

The immediate payoff was a commercialization deal in age - related macular degeneration in which Pfizer became the first big pharma company to make a move into the use of embryonic stem cells as the basis for a tissue regeneration therapy.

Most big pharma companies offer internships as do some CROs, including Cognigen.

Creating new opportunities for «all of these very talented, experienced, displaced workers» requires «getting them thinking creatively about maybe making the move from big pharma, where they've spent their careers,» to other opportunities, such as smaller, newer companies created by themselves, perhaps, or other displaced scientists.

The most important change occurring in the industry is a shift away from the traditional «big pharma» model for drug development, in which research and development are concentrated inside such companies as Pfizer, Merck, and AstraZeneca.

That has not only caused large pharma companies to back away from early - stage drug discovery, but it has forced them to pursue primarily large - market blockbuster drugs for common conditions such as heart disease and cancer, while avoiding medicines for rare diseases.

Hayward could not be specific about the cost of the technique but he says it would not affect the final price of a drug — it is «quite affordable» even for textile companies that are not as flush with cash as the pharma giants.

They have joined forces with CHS Pharma, Inc., a South Florida - based biotechnology development company that has an intellectual property portfolio for potential treatments related to ischemic stroke, dry macular degeneration as well as other age - related disorders such as Alzheimer's disease, to further develop and commercialize this promising technology.

PsychoGenics has pioneered the translation of rodent behavioral responses into robust, high throughput, high content phenotyping and its drug discovery platforms, SmartCube ®, NeuroCube ®, and PhenoCube ® have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and resulted in the discovery of several novel compounds now in clinical trials or advanced preclinical development.

With more than 1,200 international actors from 35 + countries, such as big pharma, emerging and small biotech, diagnostics companies, pre-seed / seed / Series A investors, as well as professionals from tech transfer, academia and research institutions, BioFIT is the leading partnering event in Europe for technology transfer, academia - industry collaborations and early - stage innovations in the field of Life Sciences.

Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions

Navire Pharma is a new company aimed at developing novel small - molecule inhibitors of a tyrosine - protein phosphatase called SHP2 (also known as PTPN11) for genetically - driven and treatment - resistant cancer.

The CNAG takes part in genome sequencing and analysis projects in areas as cancer genetics, rare disorders, host - pathogen interactions, the preservation of endangered species, evolutionary studies and improvement of species of agricultural interest, in collaboration with universities, hospitals, research centers and companies in the sector of biotechnology and pharma.

Massimo holds a Ph.D. from the University of Milan, where he graduated with honors, and currently serves on the boards of various companies such as Bioakos Pharma, Arriani International and Ariad Pharmaceuticals.

Massimo also serves as Executive Chairman of Bioakos Pharma, a specialty pharmaceutical company based in Florence, Italy, and focused in the areas of dermatology, gynecology and pediatrics.

TCG's investment strategy runs counter to the prevailing trend in life sciences venture capital toward assembling diversified portfolios of later stage, single product - orientated companies across multiple industry sectors, with proximity to value inflection points and the early identification of a Pharma «buyer» as key investment considerations.